This tool is donation based and free. 🙏 We're looking for donations to keep it running — $360/year covers our server costs.

$18 of $360 · 5%
Donate
This fact check is over 4 months old. The situation may have changed significantly — please recheck before relying on it.

Lithium as First-Line Bipolar Treatment Partially Accurate

“Kishi et al. (2020) demonstrated pharmacological regimens consistently outperform placebo conditions, during both maintenance and acute phases of BD. While there are many medications used to treat BD, lithium is often used as the first-line treatment (Yatham et al., 2018). Bauer (2004) demonstrated lithium’s effectiveness in preventing manic episodes, finding low relapse rates at 14% as opposed to 24% for placebos. As well as this, lithium treatment results showcase strong evidence for anti-suicidal efficacy (Ulrichsen et al., 2023). Supporting this, Song et al. (2017) investigated risk of suicide related incidents through valproate and lithium treatment, finding risk is significantly lower during lithium treatment (14% reduction), while valproate shows no significant reduction in risk. Therefore the distinction between these drugs reflects an extraordinary protective factor against suicide risk following lithium treatment, supporting lithium’s status as a first-line treatment (Yatham et al., 2018). It is also argued however, lithium’s benefits are not translated across all symptoms for BD alone. Fountoulakis et al. (2022) demonstrate for preventing acute bipolar depression, lithium is efficacious, only when combined with other medication. The varying findings signify lithium’s strengths may lie in relapse prevention for mania, while its antidepressant effects likely remain modest. Before exploring the mechanisms, it is important to note, the precise mechanisms of action of lithium are yet to be fully concluded (Thangavel et al., 2025). Some evidence suggests lithium indirectly modulates neural function. Lithium is reported to aid in restoring inhibitory control within gamma-aminobutyric acid (GABAergic) networks by reducing excitatory neurotransmission, through decreasing glutamatergic activity (Bergamelli et al., 2021; Malhi et al., 2013). Glutamate drives excitatory neuronal firing (Nicosia et al., 2024), and lithium appears to moderate this glutamatergic activity by reducing excessive glutamate-related excitation, preventing receptor overactivation associated with manic escalation (Bergamelli et al., 2021; Lee et al., 2022). Furthermore, Zanetti et al. (2015) found lithium’s effects on hippocampal glutamate to be dose-dependent and region-specific, showing evidence of bimodal modulation during depressive episodes. On the contrary, Soeiro-de-Souza et al. (2015) found lithium to have no significant effect on glutamate levels, alluding to trait-like neural differences rather than pharmacological modulation. Given the contrasting nature of Zanetti et al.’s (2015) and Soeiro-de-Souza et al.’s (2015) findings, clinically relevant insight is provided, as it suggests BD is not caused by a singular neurotransmitter dysfunction and is more likely a disorder of unstable brain signalling.”
Partially accurate
Confidence: High Checked on April 23, 2026

Summary

Lithium reliably lowers manic relapse rates (≈14 % vs 24 % with placebo) and shifts neuronal networks toward inhibition, supporting its role in relapse prevention. However, current meta‑analyses show only non‑significant reductions in suicide attempts and deaths, contradicting the claim of strong anti‑suicidal efficacy and the specific 14 % risk reduction versus valproate. The cited studies on acute depressive treatment and combined therapy are not substantiated by the

Recheck this fact Runs a fresh check with up-to-date sources

Sources 55 searched

sciencedirect.com
pmc.ncbi.nlm.nih.gov
mentalhealth.bmj.com
ncbi.nlm.nih.gov
pubmed.ncbi.nlm.nih.gov

This fact check is free and donation-based. $1 powers ~30 fact-checks.

Donate $1 to support fact-checking

Recent fact checks

Check another fact